Compare PKE & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PKE | ALT |
|---|---|---|
| Founded | 1954 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.2M | 415.3M |
| IPO Year | 1994 | 2005 |
| Metric | PKE | ALT |
|---|---|---|
| Price | $30.39 | $3.37 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 235.6K | ★ 2.8M |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.69% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $79.76 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $12.41 | $2.87 |
| 52 Week High | $29.85 | $7.73 |
| Indicator | PKE | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 65.03 | 44.78 |
| Support Level | $17.99 | $2.89 |
| Resistance Level | N/A | $4.25 |
| Average True Range (ATR) | 1.30 | 0.18 |
| MACD | 0.16 | 0.06 |
| Stochastic Oscillator | 82.55 | 76.12 |
Park Aerospace Corp designs is an aerospace company which develops and manufactures solution and hot-melt composite materials used to produce composite structures for the aerospace markets. Its composite materials include film adhesives and lightning strike protection materials. Its composite materials are used to produce primary and secondary structures for jet engines, large and regional transport aircraft, military aircraft, Unmanned Aerial Vehicles (UAVs commonly referred to as drones), business jets, general aviation aircraft and rotary wing aircraft. The Company's products are sold to customers in North America, Asia and Europe.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.